HCPCS J0576: Buprenorphine Extended-Release (Brixadi) Injection, 1 mg

HCPCS Level II code J0576 denotes the injectable extended-release formulation of buprenorphine (Brixadi), billed per 1 mg unit. As a long-acting buprenorphine product for treatment of opioid use disorder, this code matters nationally because it supports access to medication-assisted treatment options that can improve adherence and reduce overdose risk. Payers regulate coverage and reimbursement for extended-release buprenorphine differently, which affects site-of-care decisions and patient access across outpatient and clinic settings.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage patterns, common billing modifiers encountered for injectable therapies, and clinical context explaining the administration setting and unit-based billing implications. The publication highlights benchmarks and policy considerations relevant to national payers and providers, including how unit dosing influences cost-per-administration calculations and documentation requirements for administered injectable medications.

This summary equips billing managers, clinicians, and policy analysts with a concise reference to HCPCS Level II code J0576, clarifying its clinical role, typical site of service, and the payer landscape that shapes access to extended-release buprenorphine therapies.

Billing Code Overview

HCPCS Level II code J0576 describes an injection of buprenorphine extended-release (Brixadi), 1 mg. This code represents a single unit of the long-acting buprenorphine formulation used for medication-assisted treatment of opioid use disorder.

Service Type: Medication administration (injectable long-acting opioid partial agonist)

Typical Site of Service: Outpatient clinic, specialty addiction treatment center, or office-based behavioral health setting where injectable medications are administered

Clinical Context

A 34-year-old patient with moderate to severe opioid use disorder presents to an outpatient addiction medicine clinic for administration of long-acting injectable buprenorphine (Brixadi). The patient is medically stabilized on sublingual buprenorphine or has completed a brief inpatient induction and meets criteria for transition to extended-release injectable therapy to improve adherence. The clinic visit includes verification of identity, review of recent urine drug screen, assessment of withdrawal symptoms and cravings, documentation of informed consent for injection therapy, and review of allergies and concomitant medications. The medication J0576 (buprenorphine extended-release, Brixadi) is prepared by licensed staff and administered via subcutaneous injection in the upper arm, abdomen, or buttock depending on formulation and clinical judgment. After injection, the patient is observed in clinic for a monitored period (typically 15–30 minutes) for immediate adverse reactions, with vitals recorded and counseling provided regarding injection-site care, overdose risk, and follow-up scheduling. Subsequent visits occur at recommended intervals (weekly to monthly) for clinical monitoring, behavioral counseling, and repeat injections as clinically indicated.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When work required to prepare or administer the injection is substantially greater than typical (rare for standard injections).

Taxonomy Code	Specialty	Notes
`2084P0200X`	Addiction Medicine Physician	Physicians who diagnose and manage opioid use disorder and deliver medication-assisted treatment.
`208D00000X`	Psychiatrist	Provides co-management, assessment of comorbid psychiatric conditions, and prescribing when credentialed.
`363L00000X`	Nurse Practitioner	NP providing office-based medication-assisted treatment and administering injections per state scope.
`363A00000X`	Physician Assistant	PA delivering injections and clinic follow-up under supervising physician.
`164W00000X`	Family Medicine Physician	Primary care clinicians who initiate and maintain buprenorphine extended-release as part of office-based treatment.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Primary indication for buprenorphine extended-release therapy to reduce opioid use and prevent withdrawal.
`F11.21`	Opioid dependence, in remission	Patients in remission may receive medication-assisted treatment to maintain recovery and prevent relapse.
`F11.10`	Opioid abuse, uncomplicated	May be used in some payer guidance for patients with opioid use disorder meeting criteria for treatment.
`F11.23`	Opioid dependence with withdrawal	Relevant when addressing withdrawal symptoms and initiating or transitioning to extended-release buprenorphine.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing opioid agonist therapy when documenting chronic medication treatment plans.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular)	Often used to report the administration service for an injectable medication when payer rules require a CPT for administration separate from the J‑code.
`99401`	Preventive medicine counseling, individual, 15 minutes (historical example)	Counseling and brief behavioral interventions provided at visits; ensure correct current CPT code per payer for substance use counseling.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, 3–10 minutes	Represents brief counseling codes clinicians may use for adjunct behavioral interventions; select appropriate counseling CPTs for substance use as applicable.
`99408`	Alcohol and/or substance abuse structured screening and brief intervention services, 15–30 minutes	Used when structured SBIRT services are delivered at the visit in conjunction with medication administration.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity	Common E/M code for routine follow-up visits where injection `J0576` is administered and interval assessment is performed.

OpenPayer

Summary & Overview